Daiichi Clot-Buster Wins a NICE Approval, But Still Faces an Uphill Challenge
As the fourth market entrant in a competitive group of new-age anticoagulants, Daiichi Sankyo’s Lixiana (edoxaban) has a long way to go. Luckily, it got a boost in the U.K. that could help it gain momentum.